Dalton Heidi J, Garcia-Filion Pamela, Holubkov Richard, Moler Frank W, Shanley Thomas, Heidemann Sabrina, Meert Kathleen, Berg Robert A, Berger John, Carcillo Joseph, Newth Christopher, Harrison Richard, Doctor Allan, Rycus Peter, Dean J Michael, Jenkins Tammara, Nicholson Carol
1Department of Child Health, Critical Care Medicine, Phoenix Children's Hospital and University of Arizona College of Medicine-Phoenix, Phoenix, AZ. 2Critical Care Medicine, Phoenix Children's Hospital, Phoenix, AZ. 3Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT. 4Department of Pediatrics, University of Michigan, Ann Arbor, MI. 5Department of Pediatrics, Children's Hospital of Michigan, Detroit, MI. 6Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA. 7Department of Pediatrics, Children's National Medical Center, Washington, DC. 8Department of Critical Care and Anesthesia, Children's Hospital of Pittsburgh, Pittsburgh, PA. 9Department of Anesthesiology and Critical Care Medicine, Children's Hospital Los Angeles, Los Angeles, CA. 10Department of Pediatrics, University of California at Los Angeles, Los Angeles, CA. 11Departments of Pediatrics and Biochemistry, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO. 12The Extracorporeal Life Support Organization, Ann Arbor, MI. 13Pediatric Trauma and Critical Illness Branch, Eunice Kennedy Shriver National Institutes of Child Health and Human Development, The National Institutes of Health, Bethesda, MD.
Pediatr Crit Care Med. 2015 Feb;16(2):167-74. doi: 10.1097/PCC.0000000000000317.
Changes in technology and increased reports of successful extracorporeal life support use in patient populations, such as influenza, cardiac arrest, and adults, are leading to expansion of extracorporeal life support. Major limitations to extracorporeal life support expansion remain bleeding and thrombosis. These complications are the most frequent causes of death and morbidity. As a pilot project to provide baseline data for a detailed evaluation of bleeding and thrombosis in the current era, extracorporeal life support patients were analyzed from eight centers in the Eunice Kennedy Shriver National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network.
Retrospective analysis of patients (< 19 yr) reported to the Extracorporeal Life Support Organization registry from eight Collaborative Pediatric Critical Care Research Network centers between 2005 and 2011.
Tertiary children's hospitals within the Collaborative Pediatric Critical Care Research Network.
The study cohort consisted of 2,036 patients (13% with congenital diaphragmatic hernia).
None.
In the cohort of patients without congenital diaphragmatic hernia (n = 1,773), bleeding occurred in 38% of patients, whereas thrombosis was noted in 31%. Bleeding and thrombosis were associated with a decreased survival by 40% (relative risk, 0.59; 95% CI, 0.53-0.66) and 33% (odds ratio, 0.67; 95% CI, 0.60-0.74). Longer duration of extracorporeal life support and use of venoarterial cannulation were also associated with increased risk of bleeding and/or thrombotic complications and lower survival. The most common bleeding events included surgical site bleeding (17%; n = 306), cannulation site bleeding (14%; n = 256), and intracranial hemorrhage (11%; n = 192). Common thrombotic events were clots in the circuit (15%; n = 274) and the oxygenator (12%; n = 212) and hemolysis (plasma-free hemoglobin > 50 mg/dL) (10%; n = 177). Among patients with congenital diaphragmatic hernia, bleeding and thrombosis occurred in, respectively, 45% (n = 118) and 60% (n = 159), Bleeding events were associated with reduced survival (relative risk, 0.62; 95% CI, 0.46-0.86) although thrombotic events were not (relative risk, 0.92; 95% CI, 0.67-1.26).
Bleeding and thrombosis remain common complications in patients undergoing extracorporeal life support. Further research to reduce or eliminate bleeding and thrombosis is indicated to help improve patient outcome.
技术的变革以及诸如流感、心脏骤停和成人等患者群体中体外生命支持成功应用的报告增多,正促使体外生命支持的应用范围不断扩大。体外生命支持扩展的主要限制因素仍然是出血和血栓形成。这些并发症是死亡和发病的最常见原因。作为一个为详细评估当前时代出血和血栓形成提供基线数据的试点项目,对尤尼斯·肯尼迪·施赖弗国家儿童健康与人类发展研究所协作儿科重症监护研究网络中8个中心的体外生命支持患者进行了分析。
对2005年至2011年间8个协作儿科重症监护研究网络中心向体外生命支持组织登记处报告的19岁以下患者进行回顾性分析。
协作儿科重症监护研究网络内的三级儿童医院。
研究队列包括2036例患者(13%患有先天性膈疝)。
无。
在无先天性膈疝的患者队列(n = 1773)中,38%的患者发生出血,而31%的患者出现血栓形成。出血和血栓形成分别使生存率降低40%(相对风险,0.59;95%可信区间,0.53 - 0.66)和33%(比值比,0.67;95%可信区间,0.60 - 0.74)。体外生命支持时间延长和使用动静脉插管也与出血和/或血栓形成并发症风险增加及生存率降低相关。最常见的出血事件包括手术部位出血(17%;n = 306)、插管部位出血(14%;n = 256)和颅内出血(11%;n = 192)。常见的血栓形成事件是回路中的血栓(15%;n = 274)、氧合器中的血栓(12%;n = 212)和溶血(血浆游离血红蛋白>50 mg/dL)(10%;n = 177)。在患有先天性膈疝的患者中,出血和血栓形成的发生率分别为45%(n = 118)和60%(n = 159)。出血事件与生存率降低相关(相对风险,0.62;95%可信区间,0.46 - 0.86),而血栓形成事件则不然(相对风险,0.92;95%可信区间,0.67 - 1.26)。
出血和血栓形成仍然是接受体外生命支持患者的常见并发症。需要进一步研究以减少或消除出血和血栓形成,以帮助改善患者预后。